{
  "chapter": "Immunology-Transplant Immunology",
  "questions": [
    {
      "q_no": 1,
      "question": "A 45-year-old man with end-stage renal disease is scheduled for a kidney transplant. The best match for a donor kidney is from his identical twin brother. Which type of graft will this procedure involve?",
      "options": {
        "A": "Autograft",
        "B": "Isograft",
        "C": "Allograft",
        "D": "Xenograft"
      },
      "correct_answer": "B",
      "explanation": "the case of identical twins. Since there is no genetic difference between them, the transplant is not rejected by the recipient’s immune system. Types of Grafts: Autograft (Option A ruled out) Graft taken from and used on the same individual. Isograft Graft between genetically identical individuals (e.g., identical twins). No rejection due to identical genetic makeup. Allograft (formerly Homograft ) (Option C ruled out) Graft between two genetically different individuals of the same species. Commonly used in clinical transplantation. Requires immunosuppressive therapy to prevent rejection. Xenograft (formerly Heterograft ) (Option D ruled out) Graft between individuals of different species. Higher rejection rate due to significant genetic differences. Reference: Textbook of Microbiology, Ananthanarayan & Paniker, 10th Edition, Page 185, 186",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 2,
      "question": "In pre-transplant testing, which of the following methods is most commonly used to assess HLA compatibility between a kidney transplant donor and recipient?",
      "options": {
        "A": "Mixed Lymphocyte Reaction (MLR)",
        "B": "Microcytotoxicity Test",
        "C": "Histocompatibility Testing",
        "D": "ABO Blood Group Compatibility"
      },
      "correct_answer": "B",
      "explanation": "an individual's lymphocytes and uses antibodies against HLA antigens to determine compatibility. Pre-Transplant Testing and Matching: Histocompatibility Testing (Option C ruled out) Assesses compatibility between donor and recipient to reduce graft rejection risk. ABO Blood Group Compatibility (Option D ruled out) Essential for transplantation. Recipient’s plasma must not contain antibodies against the donor's RBC antigens. HLA Compatibility Key to allograft success. Human Leukocyte Antigen (HLA) System : Major histocompatibility complex in humans. Matching HLA antigens between donor and recipient improves graft acceptance. HLA Typing Methods Microcytotoxicity Test : Uses antibodies to target specific HLA antigens. Destruction of targeted cells indicates HLA type. Molecular Methods : Techniques like RFLP (Restriction Fragment Length Polymorphism) and PCR for precise HLA gene identification. Tissue Matching After identifying HLA-compatible donors, tissue matching selects the most suitable donor. Mixed Lymphocyte Reaction (MLR) : (Option A ruled out) Donor and recipient lymphocytes are cultured together. Incompatibility triggers the recipient’s T cells to undergo blast transformation, indicating rejection risk. Reference: Textbook of Microbiology, Ananthanarayan & Paniker, 10th Edition, Page 185, 187, 188, 193, 194, 195",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 3,
      "question": "A 42-year-old woman is being considered for a liver transplant. Her doctors have found a donor with an identical ABO blood group but only partial HLA matching. Which additional test should be performed to assess compatibility further and reduce graft rejection risk?",
      "options": {
        "A": "Coombs cross-match",
        "B": "Microcytotoxicity testty",
        "C": "Restriction Fragment Length Polymorphism (RFLP)",
        "D": "ABO blood group compatibility"
      },
      "correct_answer": "A",
      "explanation": "against the donor's cells, ensuring better compatibility and reducing the risk of rejection. Ideal Versus Practical Matching in Transplantation: Histocompatibility Importance Minimising antigenic differences reduces graft rejection. Perfect antigen matching is rarely achievable in practice. Ideal Matching Ideally, the donor and recipient are genetically identical (isograft), eliminating rejection risk. Rarely achievable except in identical twins. Practical Matching ABO Blood Group : Essential to match to avoid severe haemolytic reactions. HLA System : Priority is given to matching HLA-A, -B, and -DR antigens, crucial for graft survival. Sibling Donors : Best potential donors due to shared HLA haplotypes. Unrelated Donors : Large registries help find matches, though perfect matches are less likely than with siblings. Cross-Matching Final cross-match detects recipient antibodies against donor cells. Techniques include saline cross-match and Coombs cross-match. Immunosuppressive Therapy Lifelong therapy is essential to prevent graft rejection. Uses a combination of drugs targeting the immune system. Microcytotoxicity test (Option B) is incorrect as it is primarily used for determining HLA typing rather than assessing pre-formed antibodies. Restriction Fragment Length Polymorphism (RFLP) (Option C) is incorrect because it is a molecular method used for detailed genetic analysis, not for immediate compatibility assessment. ABO blood group compatibility (Option D) is incorrect; while it is essential for safety, it has already been established as identical, and the focus should be on assessing antibodies to prevent rejection. Reference: Textbook of Microbiology, Ananthanarayan & Paniker, 10th Edition, Page 185, 187, 188, 193, 194, 195",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 4,
      "question": "A 55-year-old woman is undergoing a kidney transplant. During the pre-transplant evaluation, it is discovered that she has pre-existing antibodies against the donor’s HLA antigens due to a previous organ transplant. Which of the following is most likely to occur immediately after transplantation?",
      "options": {
        "A": "Acute cellular rejection",
        "B": "Hyperacute rejection",
        "C": "Chronic rejection",
        "D": "Graft-versus-host disease"
      },
      "correct_answer": "B",
      "explanation": "pre-existing antibodies against the donor's antigens. This leads to immediate graft failure. Hyperacute Transplant Rejection: Definition Rapid and severe rejection occurring within hours of transplantation. Mediated by pre-existing antibodies in the recipient against donor antigens. Mechanism Antibodies bind to antigens on the graft's endothelial cells. Activation of the complement cascade leads to: Thrombosis : Blood clots form in graft vessels, blocking blood flow and causing ischemia. Inflammation : Neutrophil influx causes further graft damage. Necrosis : Tissue death due to ischemia and inflammation. Causes of Pre-existing Antibodies Prior Transplantation : Previous rejection can lead to antibody formation. Blood Transfusion : Exposure to foreign antigens can sensitize recipients. Pregnancy : Exposure to fetal antigens can trigger antibody production. Characteristics White graft response: Graft remains pale and is rapidly rejected without vascularisation. Prevention of Hyperacute Rejection: Pre-transplant Screening Essential to test for pre-existing antibodies against donor antigens (HLA and blood group). Cross-Matching Final cross-match using recipient serum and donor cells to detect last-minute incompatibilities. Treatment of Hyperacute Rejection: Graft Removal Difficult to treat; usually results in graft loss. Prompt removal of the graft is necessary to prevent complications. Type of rejection Mechanism Time after transplant Hyperacute rejection Mediated by preformed antibodies specific for antigens on graft endothelial cells, these may be natural IgM antibodies specific for blood group antigens, or may be antibodies specific for allogeneic MHC molecules that were induced by prior exposure of the organ recipient to allogeneic cells through blood transfusions, pregnancy, or transplantation of another organ Minutes to hours Acute cellular rejection CD8+ cells may directly destroy graft cells, or CD4+ cells secrete cytokines and induce inflammation, which damages the graft Anytime (most commonly first 6 months) Acute antibody-mediated (vascular, or humoral) rejection Antibodies bind to vascular endothelium and activate complement via the classical pathway. The resultant inflammation and endothelial damage cause graft failure. Chronic rejection Chronic rejection is an indolent form of graft damage that occurs over months or years, leading to progressive loss of graft function. Chronic rejection manifests as interstitial fibrosis and gradual narrowing of graft blood vessels (graft arteriosclerosis). Usually after 1st year Acute cellular rejection (Option A) is incorrect as it typically occurs days to weeks after transplantation, not immediately. Chronic rejection (Option C) is incorrect because it develops over months to years and is a slow process. Graft-versus-host disease (Option D) is incorrect, as it occurs when donor immune cells attack the recipient’s tissues, usually associated with bone marrow transplants, not kidney transplants. Reference: Textbook of Microbiology, Ananthanarayan & Paniker, 10th Edition, Page 186 Robbins and Cotran Pathologic Basis of Diseases 10th edition Page 235 236 237",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 5,
      "question": "A 45-year-old male recipient of a kidney transplant presents with a sudden increase in serum creatinine levels three days post-transplant. Laboratory tests reveal the presence of donor-specific antibodies (DSAs) and linear C4d staining in peritubular capillaries on biopsy. Which of the following statements best describes the condition?",
      "options": {
        "A": "It is primarily mediated by T-cell activation.",
        "B": "It is characterized by the presence of pre-existing antibodies against donor antigens.",
        "C": "It is commonly associated with chronic rejection mechanisms.",
        "D": "It usually resolves spontaneously without intervention."
      },
      "correct_answer": "B",
      "explanation": "antigens. (DSAs) in the serum, along with histological evidence of glomerulitis or peritubular capillaritis observed in biopsy samples. Additionally, linear C4d staining in peritubular capillaries serves as a critical marker for confirming the diagnosis. Acute Humoral Rejection (AHR): Definition Significant complication in organ transplantation, particularly in kidney transplants. Characterized by donor-specific antibodies (DSAs) targeting the vascular endothelium, leading to tissue injury and graft dysfunction. Mechanisms of AHR: Pathophysiology Binding of DSAs to donor HLA molecules activates the complement system, resulting in: Capillary Injury : Damage to peritubular capillaries is a hallmark of AHR. C4d Deposition : A key diagnostic marker; approximately 30% of acute rejection biopsies show widespread C4d staining. Histological Features : May include neutrophilic infiltration, glomerulitis, and fibrinoid necrosis in severe cases. Diagnosis: Diagnostic Criteria Combination of clinical presentation, serological testing, and histopathological findings: Histologic Evidence : Glomerulitis or peritubular capillaritis. Antibody Interaction : Linear C4d staining indicates recent antibody interaction with vascular endothelium. Detection of DSAs : Presence of DSAs in serum confirms diagnosis. Clinical Presentation: Symptoms Patients may experience: Acute Elevation in Creatinine : Noted within days to weeks post-transplant. Fever and Malaise : General systemic inflammation signs. Graft Tenderness : Possible tenderness over the transplant site. Treatment: Management Approaches Aim to reduce antibody-mediated injury: Plasmapheresis : Removes circulating antibodies. Intravenous Immunoglobulin (IVIG) : Modulates immune responses. Rituximab : Targets CD20 on B cells to reduce antibody production. Eculizumab : A complement inhibitor effective in severe AHR cases. It is primarily mediated by T-cell activation (Option A) is incorrect because AHR is primarily mediated by antibody interactions, not T-cell responses. It is commonly associated with chronic rejection mechanisms (Option C) is incorrect since AHR is an acute process, distinct from chronic rejection. It usually resolves spontaneously without intervention (Option D) is incorrect; AHR typically requires immunosuppressive treatment for resolution.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 6,
      "question": "A patient presents with increased serum creatinine levels and graft tenderness shortly after a kidney transplant. A biopsy reveals lymphocytic infiltration in the graft tissue. Which of the following best describes the underlying mechanism of acute cellular rejection (ACR)?",
      "options": {
        "A": "Antibody-mediated destruction of the graft's vascular endothelium",
        "B": "Activation of recipient T-lymphocytes recognizing donor antigens",
        "C": "Activation of the complement system leading to tissue necrosis",
        "D": "Direct damage from pre-existing antibodies against donor cells"
      },
      "correct_answer": "B",
      "explanation": "on the donor organ through direct and indirect pathways, leading to T-cell activation and infiltration into the graft tissue, causing damage. Acute Cellular Rejection (ACR): ACR is a significant concern in organ transplantation, characterized by T-lymphocyte infiltration into transplanted tissue. Occurs within days to weeks post-transplant, mediated by the recipient’s T-lymphocytes recognizing foreign antigens on the donor organ. Mechanisms of Acute Cellular Rejection: T-cell Activation: Direct Pathway: Donor dendritic cells present antigens directly to recipient T-cells. Indirect Pathway: Recipient antigen-presenting cells process and present donor antigens after donor cell death. Cytokine Release: Activated T-cells release cytokines (e.g., IL-2, TNF-alpha, IFN-gamma), promoting inflammation and immune responses. Histopathological Features: Feature Description Lymphocytic Infiltration Predominantly CD4+ and CD8+ T-lymphocytes damage graft tissue. Grading System Severity graded based on histology: Grade 0 No rejection Grade 1R Mild infiltration with minimal damage Grade 2R Moderate infiltration with significant damage Grade 3R Severe diffuse infiltration with extensive damage Clinical Presentation: Increased Serum Creatinine Levels: Indicative of kidney dysfunction. Graft Tenderness or Pain: Common in kidney and heart transplants. Fever and Malaise: Signs of systemic inflammation. Diagnosis: Serum Creatinine Measurement: To assess renal function. Biopsy of the Transplanted Organ: Evaluates for lymphocytic infiltration and histopathological changes. Treatment: Treatment Description Corticosteroids Administered intravenously to reduce inflammation. Anti-T-cell Antibodies E.g., antithymocyte globulin (ATG), and monoclonal antibodies (OKT3) targeting T-cells. Supportive Therapies Prophylactic antibiotics to prevent infections during immunosuppression. Antibody-mediated destruction of the graft's vascular endothelium (Option A) is characteristic of acute humoral rejection, not ACR. Activation of the complement system leading to tissue necrosis (Option C) : While the complement system is involved in some rejection mechanisms, it is primarily associated with humoral rejection rather than the T-cell-mediated process of ACR. Direct damage from pre-existing antibodies against donor cells (Option C) : Pre-existing antibodies play a role in hyperacute rejection, not in the T-cell mediated process of ACR. Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC3089893/ https://www.ncbi.nlm.nih.gov/books/NBK553074/ https://www.ncbi.nlm.nih.gov/books/NBK537057/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 7,
      "question": "Which factor is NOT typically associated with chronic transplant rejection?",
      "options": {
        "A": "A) Persistent low-grade immune response despite immunosuppressive therapy.",
        "B": "Inflammation during the first year post-transplant.",
        "C": "Antibody-mediated damage leading to tissue injury.",
        "D": "Non-immune factors like infections and ischemia."
      },
      "correct_answer": "B",
      "explanation": "with acute rejection . Chronic rejection is a slower, more insidious process that develops over time and is characterized by persistent immune response, antibody-mediated damage, and non-immune factors. Chronic Transplant Rejection: Definition : Chronic transplant rejection is a slow, progressive form of organ rejection occurring years post-transplantation. Characteristics of Chronic Transplant Rejection: Characteristic Description Gradual Decline in Graft Function Slow deterioration of transplanted organ function over time. Fibrosis and Scarring Chronic inflammation leads to fibrous tissue deposition, causing scarring and loss of normal organ structure. Vascular Changes Thickening and narrowing of blood vessels in the graft, reducing blood flow and causing tissue damage. Potential Contributing Factors: Chronic, Low-Grade Immune Response : Persistent immune response despite immunosuppressive therapy, causing ongoing inflammation and tissue damage. (Option A ruled out) Antibody-Mediated Damage : Antibodies bind to graft cells, activating complement, leading to cell lysis and inflammation. (Option C ruled out) Non-Immune Factors : Infections, ischemia (lack of blood flow), and medication toxicity contribute to chronic graft damage. (Option D ruled out) Challenges in Understanding and Managing Chronic Rejection: Challenge Description Complex and Multifactorial Involves multiple factors, complicating cause identification and therapy development. Limited Treatment Options Existing therapies focus on acute rejection prevention; less effective for chronic rejection. Impact on Long-Term Graft Survival Major cause of long-term graft failure. Reference: Textbook of Microbiology, Ananthanarayan & Paniker, 10th Edition, Page 73, 74, 83, 186, 188",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 8,
      "question": "Which of the following statements about acute graft-versus-host disease (aGVHD) is true?",
      "options": {
        "A": "aGVHD typically manifests within the first 30 days post-transplant.",
        "B": "The primary target organs affected are the skin, liver, and lungs.",
        "C": "Corticosteroids are the first-line treatment for managing aGVHD.",
        "D": "aGVHD is solely caused by mismatches in blood type between donor and recipient."
      },
      "correct_answer": "C",
      "explanation": "graft-versus-host disease, with about 50% of patients responding adequately. Acute Graft-Versus-Host Disease (aGVHD): Definition : aGVHD is a significant complication following allogeneic hematopoietic stem cell transplantation (HSCT) where donor immune cells attack the recipient's tissues. Onset : Typically occurs within the first 100 days post-transplant, but late-onset cases may arise. (Option A ruled out) Pathophysiology: Mechanism : Recognition of Host Tissues : Donor T cells identify host tissues as foreign. (Option D ruled out) Inflammatory Cascade : Leads to damage of host epithelial cells. Primary Target Organs : (Option B ruled out) Organ Symptoms Skin Maculopapular rash Liver Elevated bilirubin levels and liver enzymes Gastrointestinal Tract Abdominal pain, diarrhea, nausea, vomiting Phases of Pathophysiology : Activation of Antigen-Presenting Cells (APCs) : Damage from conditioning regimen releases inflammatory cytokines. Donor T Cell Activation : Proliferation and migration of donor T cells to target tissues. Tissue Destruction : Activated T cells induce apoptosis and necrosis through cytokine release (e.g., TNF-alpha, IL-114). Diagnosis: Key Diagnostic Criteria : Clinical Symptoms : Development of skin rash, gastrointestinal distress, or liver dysfunction within 100 days post-transplant. Biopsy : Histological examination helps differentiate aGVHD from other conditions (e.g., viral infections, drug reactions). Staging of Acute GVHD : Grade Description I Mild involvement II Moderate involvement III Severe involvement, poor prognosis IV Very severe involvement, high mortality risk Risk Factors: Donor-Recipient Compatibility : Mismatches in HLA and minor histocompatibility antigens increase risk. Sex Mismatch : Higher risk when female donors are paired with male recipients, especially if previously pregnant or transfused. Age of Recipient : Increased risk in older patients. Treatment: Management Focus : Immunosuppression to mitigate the immune response. First-Line Treatment : Corticosteroids (e.g., methylprednisolone). Approximately 50% of patients respond adequately. Second-Line Treatments : Janus kinase inhibitors (e.g., ruxolitinib) for steroid-resistant cases. Lack of universally accepted standards for refractory cases. Supportive Care : Essential for managing infections and nutritional needs related to gastrointestinal involvement. Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC2018687/ https://pubmed.ncbi.nlm.nih.gov/37291149/ https://pmc.ncbi.nlm.nih.gov/articles/PMC4141413/ https://pubmed.ncbi.nlm.nih.gov/28373413/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 9,
      "question": "Which of the following statements about chronic graft-versus-host disease (cGVHD) is true?",
      "options": {
        "A": "cGVHD can present with symptoms resembling those of systemic lupus erythematosus.",
        "B": "Skin manifestations may include erythema, hyperkeratosis, and desquamation.",
        "C": "The condition is primarily associated with infections rather than immune dysregulation.",
        "D": "Second-line treatments for cGVHD typically include high-dose corticosteroids."
      },
      "correct_answer": "B",
      "explanation": "hyperkeratosis, and desquamation. These symptoms arise due to the immune-mediated attack on the skin by donor T cells, leading to chronic inflammation and tissue damage. Chronic Graft-Versus-Host Disease (cGVHD): Definition : cGVHD is a significant complication following allogeneic hematopoietic stem cell transplantation (HSCT) and is a leading cause of morbidity and mortality in transplant recipients. It occurs when donor immune cells recognize recipient tissues as foreign. Pathophysiology: Mechanism : Immune Dysregulation : Donor T cells attack host tissues, leading to chronic inflammation and fibrosis. (Option C ruled out) Tissue Damage : Results in damage to various organs, resembling autoimmune diseases. Onset : Typically occurs between 80 days and 2 years post-transplant; approximately 30% are classified as de novo cases. Clinical Manifestations: Organ System Symptoms Skin Erythema, hyperkeratosis, sclerodermatous changes, desquamation Oral Cavity Xerostomia, oral ulcers, lichenoid changes Eyes Sicca syndrome (dry eyes) and discomfort Liver Cholestatic changes (elevated liver enzymes and bilirubin) Lungs Bronchiolitis obliterans syndrome (respiratory complications) Gastrointestinal Tract Anorexia, dysphagia, malabsorption, weight loss Other Manifestations : Polymyositis, serositis, and autoimmune features (less common). Diagnosis: Key Diagnostic Aspects : Clinical Examination : Assess symptoms across multiple organ systems. Biopsy : Skin or other tissue biopsies may confirm the diagnosis and exclude other conditions. NIH Criteria : Standardized criteria established for diagnosing and classifying cGVHD based on clinical manifestations. Treatment: Management Focus : Immunosuppressive therapies to control the immune response. First-Line Therapy : Corticosteroids are typically the first line of treatment; initial responses are common, but recurrences may occur upon tapering. (Option D ruled out) Second-Line Therapies : (Option D ruled out) Options Description Calcineurin Inhibitors e.g., tacrolimus Mycophenolate Mofetil Commonly used immunosuppressant Newer Agents ibrutinib or ruxolitinib for steroid-refractory cases Supportive Care : Essential for managing symptoms and complications, including infection treatment due to immunosuppression. cGVHD can present with symptoms resembling those of systemic lupus erythematosus (Option A): While cGVHD can present with a variety of symptoms, it does not primarily resemble systemic lupus erythematosus; it is characterized by immune dysregulation affecting multiple organs. Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC5216262/ https://pubmed.ncbi.nlm.nih.gov/12720215/ https://pmc.ncbi.nlm.nih.gov/articles/PMC3128905/ https://www.ncbi.nlm.nih.gov/books/NBK538235/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    },
    {
      "q_no": 10,
      "question": "Which of the following statements about post-transplant complications is true? production. antigens.",
      "options": {
        "A": "Allograft rejection primarily involves the activation of B lymphocytes leading to antibody",
        "B": "Hyperacute rejection occurs immediately due to pre-existing antibodies in the recipient.",
        "C": "Graft-versus-host reaction is less likely to occur in immunocompromised recipients.",
        "D": "Hemolytic disease of the newborn is caused by maternal incompatibility with paternal blood group"
      },
      "correct_answer": "B",
      "explanation": "recipient. recipient. These antibodies recognize and bind to the antigens on the donor graft, leading to an acute immune response that results in rapid graft failure. Post-Transplant Complications: Immune-Mediated Complications: Allograft Rejection : Occurs when the recipient's immune system attacks the transplanted organ, recognizing it as foreign. Mediated primarily by T lymphocytes, leading to tissue damage and graft failure. (Option A ruled out) Types of Allograft Rejection : Type Description First-Set Rejection Initial rejection episode after transplantation. Second-Set Rejection More rapid and aggressive response upon re-transplantation from the same donor due to immunological memory. Hyperacute Rejection Immediate graft failure due to pre-existing antibodies in the recipient targeting the graft. Graft-versus-Host (GVH) Reaction : Transplanted immune cells (T cells) attack the recipient's tissues, the reverse of typical transplant rejection. More likely in immunocompromised recipients (e.g., newborns, those on immunosuppressive therapy). (Option C ruled out) Can lead to severe conditions, such as runt disease in animals. Factors Influencing Rejection : Histocompatibility antigens (particularly the HLA system) play a crucial role. Matching donor and recipient HLA types minimizes rejection risk. Complications Related to Blood Transfusions Hemolytic Transfusion Reactions : Occur when incompatible ABO and Rh blood groups are transfused. Can trigger an immune response, leading to red blood cell destruction, kidney failure, or death. Hemolytic Disease of the Newborn : (Option D ruled out) Rh incompatibility between mother and fetus can lead to fetal red blood cell destruction. Maternal sensitization to fetal Rh antigens during pregnancy leads to antibody production that crosses the placenta. Infectious Complications : Risks include transmission of infectious agents (e.g., HIV, hepatitis B and C, syphilis, malaria) through transfusions, despite screening procedures. Reference: Textbook of Microbiology, Ananthanarayan & Paniker, 10th Edition, Page 186, 187, 188, 194, 195, 196, 197",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Immunology-Transplant Immunology"
    }
  ]
}
